**Background**
Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperplasia and the infiltration of immune cells. The pathogenesis of this condition is heavily driven by the IL-23/IL-17 axis, where the transcription factor retinoic acid-related orphan receptor gamma t (RORγt) serves as the master regulator. RORγt is essential for the differentiation of TH17 cells and the subsequent production of pro-inflammatory cytokines, including IL-17 and IL-22. Because of its central role in orchestrating the inflammatory response, RORγt has become an attractive therapeutic target for the treatment of various inflammatory diseases, particularly chronic plaque psoriasis. In this context, we will introduce an orally active RORγt inverse agonist – Cedirogant.
**Definition**
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist with the molecular formula C24H20Cl3F3N2O3.
**In Vitro Studies**
According to the Cedirogant description, this compound is designed to inhibit the activity of RORγt to suppress the differentiation of TH17 cells. In terms of Cedirogant in vitro activity, the compound targets the RORγt transcription factor to reduce the production of IL-17 and IL-22, which are key drivers of the inflammatory cascade in skin tissues. Research indicates that Cedirogant has significant potential for the study of chronic plaque psoriasis by modulating these pathways. For researchers requiring specific Cedirogant technical information regarding its chemical properties, it possesses a molecular weight of 547.78 and is identified by CAS No. 2055496-11-0. In conclusion, Cedirogant is a potent RORγt inverse agonist that holds promise as a tool for investigating the pharmacological management of inflammatory diseases and psoriasis.
Keywords
Cedirogant, 2055496-11-0, ABBV-157, ABBV157, ABBV 157, ROR, RAR-related orphan receptor, RORγt, inverse, agonist, psoriasis, Inhibitor, inhibitor, inhibit
References
[1] Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737.
[2] Christian Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently? Expert Opin Drug Discov. 2021 Jul 7;1-19.